Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis

Across heterogeneous study designs and patient populations found in real-world studies, the consensus 1-year fingolimod persistence rate exceeded 80%, consistent with persistence rates identified in the recently-completed trial, PREFERMS.